IXJ ETF Analysis: Global Healthcare | NYSE

Health | NYSE, USA | Market Cap: 4.191m USD | 12M Return: 19.3% | US4642873255 | Charts, Fundamentals & Technical Analysis

Pharmaceuticals, Biotechnology, Medical Devices, Healthcare Equipment
Total Rating 57
Safety 68
Buy Signal -0.08
Health
Category Rotation: -0.6
TER: 0.42%
AUM: 4.19B
Avg Turnover: 15.8M
Risk 3d forecast
Volatility16.0%
VaR 5th Pctl2.79%
VaR vs Median-3.06%
Reward TTM
Sharpe Ratio0.94
Rel. Str. IBD62.1
Rel. Str. Peer Group9.4
Character TTM
Beta0.178
Beta Downside0.189
Hurst Exponent0.451
Drawdowns 3y
Max DD18.14%
CAGR/Max DD0.49
CAGR/Mean DD1.55

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Seasonality 11.6 years of data

Jan +0.2% 19
Feb -1.1% 18
Mar -0.9% 5
Apr -0.2% 10
May +0.1% 5
Jun +0.9% 9
Jul +0.8% 30
Aug -0.2% 11
Sep -1.6% 29
Oct -3.0% 12
Nov +4.2% 30
Dec +0.2% 0

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: IXJ Global Healthcare

The iShares Global Healthcare ETF (IXJ) is a passively managed exchange-traded fund that tracks an underlying index composed of companies classified within the global healthcare sector by S&P Dow Jones Indices. The fund adheres to a standard index-tracking structure, investing at least 80% of its assets in the securities that make up its benchmark index, with the remaining portion permitted in derivatives such as futures, options, and swap contracts, as well as cash and cash equivalents. The 80% policy is a regulatory convention for funds marketed as tracking a specific index.

Launched in November 2001, IXJ provides exposure to healthcare equities across global markets, a sector that typically spans pharmaceuticals, biotechnology, medical devices, and healthcare services providers. As a mid-cap ETF with approximately $3.7 billion in assets, it offers investors a vehicle to participate in the performance of large and mid-sized healthcare companies considered significant to international markets by the index provider.

Headlines to Watch Out For
  • Medicare drug price negotiations expand to more drugs
  • Aging global population drives sustained healthcare demand
  • Blockbuster drug patent cliffs pressure pharma revenue
What is the price of IXJ shares?

As of September 22, 2026, the stock is trading at USD 103.18 with a total of 63,765 shares traded. Over the past week, the price has changed by +0.89%, over one month by -3.43%, over three months by +10.38% and over the past year by +19.34%.

Current recommended Stop Loss: 100.30 (which is 2.8% or 2.2 ATR below the current price).

Is IXJ a buy, sell or hold?

Global Healthcare has no consensus analysts rating.